Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This emerging Bitcoin infrastructure company is building a vertically integrated model (click to learn more) Laser Photonics Announces Strategic Milestone on Advanced Laser Shield Anti Drone System (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Eagle Pharmaceuticals Inc (EM) EGRX

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell... see more

Recent & Breaking News (EXPM:EGRX)

Eagle Pharmaceuticals Announces Divestiture of Barhemsys

GlobeNewswire January 14, 2026

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan

GlobeNewswire October 30, 2025

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

GlobeNewswire October 21, 2025

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements

GlobeNewswire October 15, 2025

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements

GlobeNewswire October 6, 2025

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years

GlobeNewswire September 17, 2025

Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors

GlobeNewswire August 28, 2025

Eagle Pharmaceuticals Announces 2025 Annual Meeting Date

GlobeNewswire August 18, 2025

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

GlobeNewswire March 31, 2025

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

GlobeNewswire March 21, 2025

Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

GlobeNewswire November 15, 2024

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

GlobeNewswire November 12, 2024

Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

GlobeNewswire October 31, 2024

INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Eagle Pharmaceuticals, Inc. On Behalf of Shareholders

ACCESS Newswire October 22, 2024

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

GlobeNewswire August 27, 2024

Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), Akero Therapeutics, Inc. (NASDAQ: AKRO), Rivian Automotive, Inc. (NASDAQ: RIVN), and QuidelOrtho Corporation (NASDAQ: QDEL)

ACCESS Newswire June 27, 2024

Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), Driven Brands Holdings Inc. (NASDAQ:DRVN), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), and Gristone bio, Inc. (NASDAQ:GRTS)

ACCESS Newswire June 14, 2024

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

GlobeNewswire May 22, 2024

Lifshitz Law PLLC Announces Investigations of Cummins Inc. (NYSE:CMI), Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), Fox Factory Holding Corp. (NASDAQ:FOXF), and Inspire Medical Systems, Inc. (NYSE:INSP)

ACCESS Newswire May 17, 2024

Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting

GlobeNewswire April 30, 2024

Podcasts